1
Country: Switzerland | Funding: $365.4M
ALENTIS Therapeutics develops novel therapeutics for the treatment of advanced liver fibrosis and liver cancer. The company is developing a portfolio of antibody-drug conjugates (ADCs) and monoclonal antibodies against its therapeutic target, claudin-1. Its unique antibodies specifically target exposed claudin-1 to open the rigid extracellular matrix, block disease signals and, in cancer, selectively kill tumor cells. ALENTIS's clinical candidates include the ADC ALE.P02 for the treatment of squamous cell carcinomas and the monoclonal antibody lixudebart for the treatment of organ fibrosis. In addition to clinical development, its preclinical programs include other anti-claudin-1 therapies, including other ADCs.
ALENTIS Therapeutics develops novel therapeutics for the treatment of advanced liver fibrosis and liver cancer. The company is developing a portfolio of antibody-drug conjugates (ADCs) and monoclonal antibodies against its therapeutic target, claudin-1. Its unique antibodies specifically target exposed claudin-1 to open the rigid extracellular matrix, block disease signals and, in cancer, selectively kill tumor cells. ALENTIS's clinical candidates include the ADC ALE.P02 for the treatment of squamous cell carcinomas and the monoclonal antibody lixudebart for the treatment of organ fibrosis. In addition to clinical development, its preclinical programs include other anti-claudin-1 therapies, including other ADCs.
2
Country: USA | Funding: $209M
Ikena Oncology is developing novel immunometabolic therapies. Its flagship drug IMG-007 is a monoclonal antibody against OX40 with an extended half-life (5 weeks) for patients with immunological, autoimmune and inflammatory diseases. IMG-007 contains a modified Fc region that blocks ADCC function, meaning signaling by activated T cells is weakened without destroying or depleting T cells. This solution has the potential to improve tolerability and increase the range of measurement, leading to the use of higher doses, increased efficacy and improved safety. The company's primary target is atopic dermatitis. In a proof-of-concept clinical trial in patients with moderate to severe atopic dermatitis, three doses of IMG-007 administered over a one-month period resulted in symptom reduction in the majority of patients. Ikena Oncology was acquired by ImageneBio
Ikena Oncology is developing novel immunometabolic therapies. Its flagship drug IMG-007 is a monoclonal antibody against OX40 with an extended half-life (5 weeks) for patients with immunological, autoimmune and inflammatory diseases. IMG-007 contains a modified Fc region that blocks ADCC function, meaning signaling by activated T cells is weakened without destroying or depleting T cells. This solution has the potential to improve tolerability and increase the range of measurement, leading to the use of higher doses, increased efficacy and improved safety. The company's primary target is atopic dermatitis. In a proof-of-concept clinical trial in patients with moderate to severe atopic dermatitis, three doses of IMG-007 administered over a one-month period resulted in symptom reduction in the majority of patients. Ikena Oncology was acquired by ImageneBio
3
Country: USA | Funding: $1.4B
ImmunityBio is a privately held immunotherapy company with one of the broadest portfolios of biological molecules spanning albumin-linked chemotherapeutic, peptides, fusion proteins, cytokine, monoclonal antibodies, adenovirus and yeast vaccine therapies.
ImmunityBio is a privately held immunotherapy company with one of the broadest portfolios of biological molecules spanning albumin-linked chemotherapeutic, peptides, fusion proteins, cytokine, monoclonal antibodies, adenovirus and yeast vaccine therapies.
4
Country: USA | Funding: $1.3B
Arcus discovers and develops innovative cancer immunotherapies based on known but under-exploited biology. Arcus’s lead program targets the adenosine pathway, which has been shown to play a significant role in driving immuno-suppression in the tumor micro-environment.
Arcus discovers and develops innovative cancer immunotherapies based on known but under-exploited biology. Arcus’s lead program targets the adenosine pathway, which has been shown to play a significant role in driving immuno-suppression in the tumor micro-environment.
5
Country: Switzerland | Funding: $1B
ADC Therapeutics is focused on the creation of proprietary Antibody Drug Conjugates (ADCs) for the therapy of both solid and hematological cancers. It uses monoclonal antibodies specific to specific tumor antigens conjugated to a innovative class of highly potent pyrrolobenzodiazepine (PBD)-based warheads to specifically kill cancer cells. The company is expanding ZYNLONTA into earlier stages of DLBCL and indolent lymphomas. In addition, IND-enabling efforts are in progress for the Company’s exatecan-based, prostate-specific membrane antigen.
ADC Therapeutics is focused on the creation of proprietary Antibody Drug Conjugates (ADCs) for the therapy of both solid and hematological cancers. It uses monoclonal antibodies specific to specific tumor antigens conjugated to a innovative class of highly potent pyrrolobenzodiazepine (PBD)-based warheads to specifically kill cancer cells. The company is expanding ZYNLONTA into earlier stages of DLBCL and indolent lymphomas. In addition, IND-enabling efforts are in progress for the Company’s exatecan-based, prostate-specific membrane antigen.
6
Country: USA | Funding: $656.4M
Astria Therapeutics discovers and develops innovative drugs for treating inflammatory conditions.
Astria Therapeutics discovers and develops innovative drugs for treating inflammatory conditions.
7
Country: USA | Funding: $513M
Zenas BioPharma is a biopharmaceutical company that focuses on developing immune-based therapies for patients.
Zenas BioPharma is a biopharmaceutical company that focuses on developing immune-based therapies for patients.
8
Country: USA | Funding: $496M
Invivyd develops antibodies to transcend the limitations of the human immune system and fight against viral infections.
Invivyd develops antibodies to transcend the limitations of the human immune system and fight against viral infections.
9
Country: USA | Funding: $397M
Evelo is pioneering therapies that modulate systemic immune response by acting on the gut-body network - monoclonal microbials. They have the potential to treat many diseases, including inflammatory disease, cancer, autoimmune disease, metabolic, neurobehavior and neuroinflammatory diseases.
Evelo is pioneering therapies that modulate systemic immune response by acting on the gut-body network - monoclonal microbials. They have the potential to treat many diseases, including inflammatory disease, cancer, autoimmune disease, metabolic, neurobehavior and neuroinflammatory diseases.
10
Country: Belgium | Funding: $325.6M
AgomAb Therapeutics is a Company is developing growth factor-mimetic agonistic monoclonal antibodies to regenerate damaged tissues.
AgomAb Therapeutics is a Company is developing growth factor-mimetic agonistic monoclonal antibodies to regenerate damaged tissues.
11
Country: Denmark | Funding: $249.6M
ADCendo develops antibody-drug conjugates (ADCs) for the treatment of cancers with high unmet medical needs. The company is developing two technologies: ADCE-T02, which combines an optimized monoclonal antibody targeting tissue factor (overexpressed in numerous solid tumor indications) with a next-generation linker and exatecan delivery technology, providing higher efficacy and improved tolerability. The second candidate is ADCE-D01 - a first-in-class ADC targeting uPARAP, an endocytic receptor overexpressed in a wide range of mesenchymal tumors, including soft tissue sarcomas, osteosarcoma, GISTs, mesothelioma and glioblastoma.
ADCendo develops antibody-drug conjugates (ADCs) for the treatment of cancers with high unmet medical needs. The company is developing two technologies: ADCE-T02, which combines an optimized monoclonal antibody targeting tissue factor (overexpressed in numerous solid tumor indications) with a next-generation linker and exatecan delivery technology, providing higher efficacy and improved tolerability. The second candidate is ADCE-D01 - a first-in-class ADC targeting uPARAP, an endocytic receptor overexpressed in a wide range of mesenchymal tumors, including soft tissue sarcomas, osteosarcoma, GISTs, mesothelioma and glioblastoma.
12
Country: Ireland | Funding: $245.9M
SynOx is developing emactuzumab, a best-in-class CSF1R targeted therapeutic antibody designed to target and deplete tumour-associated macrophages in the tumour tissue.
SynOx is developing emactuzumab, a best-in-class CSF1R targeted therapeutic antibody designed to target and deplete tumour-associated macrophages in the tumour tissue.
13
Country: France | Funding: $179.5M
HiFiBiO Therapeutics is biotherapeutics company mobilizing the human immune system to combat disease. We integrate deep-rooted biological expertise with our comprehensive single-cell profiling technologies to rapidly discover and advance a pipeline of antibody drugs to treat cancer and autoimmune disorders. We also aspire to benefit patients through open-innovation partnerships with industry and academia.
HiFiBiO Therapeutics is biotherapeutics company mobilizing the human immune system to combat disease. We integrate deep-rooted biological expertise with our comprehensive single-cell profiling technologies to rapidly discover and advance a pipeline of antibody drugs to treat cancer and autoimmune disorders. We also aspire to benefit patients through open-innovation partnerships with industry and academia.
14
Country: USA | Funding: $176M
Santa Ana Bio is a biotechnology company focusing on precision immunology for autoimmune and inflammatory diseases.
Santa Ana Bio is a biotechnology company focusing on precision immunology for autoimmune and inflammatory diseases.
15
Country: USA | Funding: $22.3M
Aqualung Therapeutics is developing a novel, anti-inflammatory monoclonal antibody strategy to treat serious unchecked inflammation.
Aqualung Therapeutics is developing a novel, anti-inflammatory monoclonal antibody strategy to treat serious unchecked inflammation.
16
Country: Australia | Funding: A$10M
HaemaLogiX develops novel immuno-oncology and immunotherapy drugs for the treatment of blood cancers and B-cell diseases. Unlike existing treatments, HaemaLogiX products preserve the patient's immune system, helping fight cancer and maintain resistance to life-threatening infections during treatment. HaemaLogiX drugs are monoclonal antibodies that bind to unused and unique targets - KMA (kappa myeloma antigen) and LMA (lambda myeloma antigen) antigens - which are absent on normal plasma cells. The company is also developing KMA.CAR-T cell therapy, designed for separate subsets of multiple myeloma patients to KappaMab who have become resistant to standard treatments. The binding arm of KappaMab is connected to two proteins inside the T cell that are capable of stimulating and signalling to the T cell that it should destroy the KMA-positive myeloma cell.
HaemaLogiX develops novel immuno-oncology and immunotherapy drugs for the treatment of blood cancers and B-cell diseases. Unlike existing treatments, HaemaLogiX products preserve the patient's immune system, helping fight cancer and maintain resistance to life-threatening infections during treatment. HaemaLogiX drugs are monoclonal antibodies that bind to unused and unique targets - KMA (kappa myeloma antigen) and LMA (lambda myeloma antigen) antigens - which are absent on normal plasma cells. The company is also developing KMA.CAR-T cell therapy, designed for separate subsets of multiple myeloma patients to KappaMab who have become resistant to standard treatments. The binding arm of KappaMab is connected to two proteins inside the T cell that are capable of stimulating and signalling to the T cell that it should destroy the KMA-positive myeloma cell.
